[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Olaparib",
            "Result": [
                "Score: -2 - Reasoning: The hypothesis that Olaparib worsens breast cancer patient outcomes is clearly refuted by strong and consistent evidence across all provided abstracts (PMIDs: 466915, 550774, 242412, 873872, 855109). Each study demonstrates a statistically significant improvement in progression-free survival (PFS) and/or objective response rate (ORR) for patients treated with Olaparib compared to chemotherapy or placebo, indicating better clinical outcomes rather than a worsening. For example, PMID: 466915 reports that Olaparib significantly prolongs PFS (9.8 vs. 5.4 months), and PMID: 550774 shows a similar PFS benefit (7.8 vs. 4.2 months), both with manageable safety profiles. Thus, the data robustly contradict the hypothesis of Olaparib worsening patient outcomes."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 466915. **Title:** Olaparib as a Targeted Therapy in *BRCA*-Mutated Metastatic Breast Cancer: A Phase III Randomized Controlled Trial Demonstrating Significant Improvement in Progression-Free Survival  \n\n**Background:** Poly(ADP-ribose) polymerase (PARP) inhibitors, such as olaparib, have emerged as a promising therapeutic strategy for *BRCA*-mutated cancers due to their synthetic lethality in homologous recombination-deficient tumors. Despite preclinical efficacy, robust clinical data on olaparib in metastatic breast cancer (MBC) remain limited. This phase III trial evaluated the efficacy and safety of olaparib versus standard chemotherapy in patients with *BRCA1/2*-mutated, HER2-negative MBC.  \n\n**Methods:** In this multicenter, open-label, randomized controlled trial, 302 patients with *BRCA1/2*-mutated MBC were assigned 1:1 to receive either olaparib (300 mg twice daily) or physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or eribulin). The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using a Cox proportional hazards model with a two-sided \u03b1 of 0.05.  \n\n**Results:** After a median follow-up of 24.5 months, olaparib significantly prolonged median PFS compared to chemotherapy (9.8 vs. 5.4 months; hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.40\u20130.68; *p* < 0.001). The ORR was higher with olaparib (52.3% vs. 28.7%, *p* = 0.002). Interim OS data showed a trend favoring olaparib (HR 0.76, 95% CI 0.55\u20131.05, *p* = 0.09). Grade \u22653 adverse events were less frequent with olaparib (36.1% vs. 50.4%), with anemia (16.2%) and fatigue (8.5%) being the most common.  \n\n**Conclusion:** Olaparib demonstrated a statistically significant and clinically meaningful improvement in PFS over standard chemotherapy in *BRCA*-mutated MBC, with a favorable safety profile. These findings support olaparib as a first-line targeted therapy for this molecularly defined population.  \n\n**Trial Registration:** ClinicalTrials.gov, NCT03012321.  \n\n**Keywords:** PARP inhibitor, *BRCA* mutation, metastatic breast cancer, targeted therapy, progression-free survival.  \n\n(Word count: 275)\n\n---\n\nPMID: 550774. **Title:** Olaparib as a Targeted Therapy in BRCA-Mutated Breast Cancer: A Phase III Randomized Controlled Trial Demonstrating Significant Improvement in Progression-Free Survival  \n\n**Abstract**  \n\n**Introduction:** Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising therapeutic strategy for BRCA-mutated breast cancer. Olaparib, a potent PARP inhibitor, has shown preclinical efficacy in inducing synthetic lethality in BRCA-deficient tumors. This Phase III randomized controlled trial (RCT) evaluated the efficacy and safety of Olaparib compared to standard chemotherapy in patients with HER2-negative, BRCA-mutated metastatic breast cancer.  \n\n**Methods:** In this multicenter, open-label trial, 302 patients were randomized 1:1 to receive either Olaparib (300 mg twice daily) or physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or eribulin). The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with a two-sided alpha of 0.05.  \n\n**Results:** Median PFS was significantly longer in the Olaparib group (7.8 months [95% CI: 7.2\u20139.1]) compared to the chemotherapy group (4.2 months [95% CI: 3.8\u20135.1]; hazard ratio [HR] 0.52, 95% CI: 0.41\u20130.66; p < 0.001). The ORR was 59.9% (95% CI: 52.4\u201367.1) for Olaparib versus 28.8% (95% CI: 22.3\u201336.0) for chemotherapy (p < 0.001). Interim OS data showed a trend favoring Olaparib (HR 0.75, 95% CI: 0.56\u20131.01; p = 0.06). Grade \u22653 adverse events were less frequent with Olaparib (36.5%) versus chemotherapy (50.2%), with anemia (16.1%) and fatigue (9.8%) being the most common Olaparib-related toxicities.  \n\n**Discussion:** Olaparib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR compared to standard chemotherapy in BRCA-mutated metastatic breast cancer, with a favorable safety profile. These findings support the use of Olaparib as a first-line targeted therapy in this molecularly defined population. Further follow-up is warranted to confirm OS benefits.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Keywords:** Olaparib, PARP inhibitor, BRCA mutation, metastatic breast cancer, targeted therapy, progression-free survival\n\n---\n\nPMID: 242412. **Title:** Efficacy of Olaparib in Improving Outcomes for Patients with BRCA-Mutated Metastatic Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Background:** Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising therapeutic strategy for BRCA-mutated breast cancer. Olaparib, a potent PARP inhibitor, has shown preclinical efficacy in inducing synthetic lethality in BRCA-deficient tumors. This Phase III trial evaluated the clinical benefit of Olaparib versus standard chemotherapy in patients with HER2-negative metastatic breast cancer (mBC) harboring germline BRCA1/2 mutations.  \n\n**Methods:** In this multicenter, open-label, randomized controlled trial, 302 patients with confirmed germline BRCA1/2 mutations and HER2-negative mBC were enrolled. Participants were randomized 1:1 to receive either oral Olaparib (300 mg twice daily) or physician\u2019s choice of single-agent chemotherapy (capecitabine, vinorelbine, or eribulin). The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with significance set at p < 0.05.  \n\n**Results:** Median PFS was significantly longer in the Olaparib group compared to the chemotherapy group (7.8 months vs. 4.2 months; hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.45\u20130.76; p < 0.001). The 12-month PFS rate was 35.2% for Olaparib versus 12.6% for chemotherapy. ORR was higher with Olaparib (52.4% vs. 28.6%, p = 0.002). Interim OS analysis showed a trend favoring Olaparib (HR 0.82, 95% CI 0.62\u20131.09, p = 0.16), though not statistically significant. Grade \u22653 adverse events were less frequent with Olaparib (36.7% vs. 50.4%), with anemia (16.2%) being the most common Olaparib-related toxicity.  \n\n**Conclusion:** Olaparib significantly improves PFS and ORR compared to standard chemotherapy in patients with BRCA-mutated HER2-negative mBC, with a manageable safety profile. These findings support Olaparib as a first-line therapeutic option for this molecularly defined population. ClinicalTrials.gov Identifier: NCTXXXXXXX.  \n\n(Word count: 258)\n\n---\n\nPMID: 873872. **Title:** *Efficacy of Olaparib in Advanced Breast Cancer with Germline BRCA Mutations: A Phase III Randomized Controlled Trial*  \n\n**Objective:** To evaluate the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with HER2-negative advanced breast cancer harboring germline BRCA1/2 mutations.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by prior chemotherapy lines (0\u20131 vs. \u22652) and hormone receptor status (positive vs. negative).  \n\n**Participants:** Eligible participants were adults with confirmed HER2-negative metastatic or locally advanced breast cancer and pathogenic germline BRCA1/2 mutations. A total of 302 patients were enrolled from 97 sites across 19 countries.  \n\n**Interventions:** Patients were randomized 2:1 to receive oral olaparib (300 mg twice daily) or placebo until disease progression or unacceptable toxicity. All participants received best supportive care.  \n\n**Main Outcome Measures:** The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (RECIST v1.1). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median PFS was significantly longer in the olaparib group (7.8 months [95% CI, 6.4\u20139.1]) compared to placebo (4.2 months [95% CI, 3.0\u20135.7]; hazard ratio [HR] 0.58, 95% CI 0.43\u20130.80; *p* = 0.0009). ORR was 52% (95% CI, 45\u201359) with olaparib versus 23% (95% CI, 15\u201332) with placebo (*p* < 0.001). Interim OS analysis showed a trend favoring olaparib (HR 0.82, 95% CI 0.55\u20131.21; *p* = 0.32). Grade \u22653 adverse events occurred in 40% of olaparib-treated patients (most commonly anemia [16%]) versus 23% with placebo.  \n\n**Conclusions:** Olaparib significantly improved PFS and ORR in patients with germline BRCA-mutated advanced breast cancer, with a manageable safety profile. These findings support olaparib as a targeted therapeutic option for this molecularly defined population.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 855109. **Title: Olaparib Significantly Improves Progression-Free Survival in Patients with BRCA-Mutated Metastatic Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Abstract**  \n\n**Introduction:** Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising therapeutic strategy for BRCA-mutated breast cancer. Olaparib, a potent PARP inhibitor, has shown preclinical efficacy in homologous recombination repair-deficient tumors. This phase III trial evaluated the efficacy and safety of olaparib versus standard chemotherapy in patients with HER2-negative metastatic breast cancer (mBC) harboring germline BRCA1/2 mutations.  \n\n**Methods:** In this multicenter, open-label, randomized controlled trial, 302 patients with confirmed germline BRCA1/2 mutations and HER2-negative mBC were enrolled. Participants were randomized 1:1 to receive either oral olaparib (300 mg twice daily) or physician\u2019s choice of single-agent chemotherapy (capecitabine, vinorelbine, or eribulin). The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with a two-sided p-value <0.05 considered significant.  \n\n**Results:** After a median follow-up of 24.5 months, olaparib demonstrated a statistically significant improvement in median PFS compared to chemotherapy (9.8 months vs. 5.4 months; hazard ratio [HR] 0.52; 95% confidence interval [CI] 0.40\u20130.68; p<0.001). The ORR was significantly higher in the olaparib group (52.3% vs. 28.6%; p=0.002). Interim OS analysis showed a trend favoring olaparib (HR 0.78; 95% CI 0.56\u20131.09; p=0.14), though data were immature. Treatment-related adverse events (AEs) were consistent with prior reports, with fewer grade \u22653 AEs in the olaparib arm (36.7% vs. 50.2%).  \n\n**Discussion:** Olaparib significantly prolonged PFS and improved response rates in patients with BRCA-mutated mBC, establishing its role as a first-line therapeutic option. The favorable safety profile further supports its clinical utility. These findings underscore the importance of PARP inhibition in BRCA-associated breast cancer and warrant further investigation into combination strategies and long-term survival outcomes.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Keywords:** Olaparib, PARP inhibitor, BRCA mutation, metastatic breast cancer, progression-free survival\n\nAvailable PMIDs for Citation: 466915, 550774, 242412, 873872, 855109\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Olaparib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Olaparib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Olaparib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Olaparib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Olaparib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Olaparib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Olaparib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Olaparib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Olaparib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Olaparib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Olaparib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/466915/",
                    "https://pubmed.ncbi.nlm.nih.gov/550774/",
                    "https://pubmed.ncbi.nlm.nih.gov/242412/",
                    "https://pubmed.ncbi.nlm.nih.gov/873872/",
                    "https://pubmed.ncbi.nlm.nih.gov/855109/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]